TSX Venture: QPT
EDMONTON, Sept. 6, 2016 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products to improve the quality of life, today announces the appointment of the Haft Group, a New York based communications and advisory firm with 30 years' experience, to provide financial and investor relations advisory services for the US and Canadian markets.
"I am very pleased to work with the Haft Group to expand our outreach and presence with the investment community and our shareholders" said Dr. Madi Madiyalakan, Chief Executive Officer of Quest and OncoQuest. "Quest's current business model, with a primary focus geared to the development of breakthrough cancer research, operates through its 5 independent business units under the Quest umbrella. Each business unit has its unique technology in (i) combinatorial immunotherapy through its subsidiary OncoQuest Inc.; (ii) immunotherapy in China through OncoVent Co., Ltd.; (iii) targeted cancer therapy; (iv) health and consumer products; and (v) transdermal delivery technology. Together they all add value to Quest." added Dr. Madiyalakan. "Through the Haft Group and the Company's advisors, Quest will address both the US and Canadian financial markets, with the focus on expanding the capital and public exposure of the Company".
About Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded, Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest is developing antibody based immunotherapeutic products for cancer. In addition, the Company owns the Photodynamic Therapy technology for oncology and dermatology applications, licensed to Bioceltran Co., Ltd., a Korea based company (Bioceltran). Quest has an ownership interest in Bioceltran which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes. Quest also markets consumer health products worldwide, including Bellus Skin™ serum, a premium anti-wrinkle skin care product licensed from Korea. Quest is also developing an antibody licensed from University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.
For further information: Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: email@example.com, Internet: www.questpharmatech.com; Mr. Herb Haft, The Haft Group, Public & Investor Relations. 153 East 57 Street, New York, NY 10022. Tel: (212) 759-8865, Email: firstname.lastname@example.org